Mentor simulator was achieved after five trials in terms of the PCNL-GRS score, 14 trials in terms of the operative and fluoroscopy times and PCS perforations, and 9 trials in terms of the vascular injury. Furthermore, participants performed 20 PCA procedures with mean time to achieve successful puncture of 120AE15 seconds, mean fluoroscopy time of 27.2AE4.7 seconds, mean attempts to puncture the PCS of 1.5AE0.2, mean PCNL-GRS score of 20.3AE0.9. However, one case (5%) of colon perforation was encountered and 2 cases (10%) was associated with failed puncture.
INTRODUCTION AND OBJECTIVES: Collagenase Clostridium histolyticum (CCH) (XiaflexÒ; Endo, Chesterbrook, PA) is the first licensed drug for the treatment of Peyronie's disease (PD). Although PD is strongly associated with erectile dysfunction, there are no studies of the effects of CCH on isolated human corpus cavernosum (HCC) smooth muscle function. A clinical study did not show any significant changes on penile duplex Doppler ultrasound after four cycles of CCH (0.58 mg). We aimed to evaluate the effects of different concentrations of CCH on nitric oxide (NO)-dependent and -independent nitrergic relaxations of HCC in organ bath studies, in order to understand if CCH can improve HCC relaxation, and, thus, ED in PD patients.
METHODS: HCC samples were obtained from men undergoing penile prosthesis implantation (n [ 10). After phenylephrine (Phe) contraction, electrical field stimulation (EFS) and acetylcholine (ACh)-induced relaxation of [0.23 and 0.9 mg] CCH incubations of HCC strips were performed using organ bath preparations. HCC measurements of endothelial NO synthase, neuronal, and vascular endothelial growth factor were evaluated through immunostaining and Western blotting. Type I and III collagen levels were evaluated by Western blot analysis RESULTS: Pre-incubation with various doses of CCH did not reduce the maximal contractile response of Phe and the relaxant response to EFS (20Hz) in HCC. Nevertheless pre-incubation with CCH significantly reduced contractile tension evoked by EFS (80 Hz) by 37.5%, and increased ACh-induced relaxation (10-3M) five-fold at 0.23 and 0.9 mg. CCH appeared to be safe and possibly reduced corporal fibrosis, as well as collagen type I and III expressions in the high-dose CCH treated HCC samples when compared with the untreated HCC samples.
CONCLUSIONS: The potential relaxant effect of CCH on HCC smooth muscle may enhance parasympathetic cholinergic response and inhibit sympathetic adrenergic receptors, resulting in reduced EFSinduced contraction (80Hz). The relaxation response to CCH is likely to be dependent of NO-cGMP pathway and structural changes in HCC collagen. Incubating HCC with 0.9 mg CCH may have in vitro proerectile effects on the penile vasculature. This adds to the safety profile of CCH. More studies are required to examine the therapeutic potential of CCH pro-erectile effects with increased dosing in vivo to better address PD and the associated erectile dysfunction. METHODS: An online intervention for couples' sexual recovery was developed using mixed methods research with prostate cancer patients and their partners, tailored to treatment type and sexual orientation. The intervention consisted of modules addressing expectations for sexual and emotional sequelae of treatment, rehabilitation and guidance towards recovery of sexual intimacy and included videos, psychoeducation, couple-oriented activities, and coping strategies. Control subjects accessed the American Cancer Society's website. Couples recruited from 6 sites nationally completed validated measures at baseline and 3 and 6 months post-treatment. Group differences were assessed with t-tests for individual outcomes and the Actor-Partner Interaction Model for dyadic outcomes.
RESULTS: 142 patients treated with surgery or radiation and their partners were randomized. All couples showed an expected posttreatment decline in PROMIS Satisfaction with Sex Life, with similar declines for the intervention and control groups. Both patients and partners in the intervention arm showed increased knowledge about sexual issues at 3-months post-treatment vs baseline. Patients more engaged in the intervention evidenced improved ability to communicate about sex with their partners than those less engaged. Dyadic analysis showed that higher complicated grief scores and negative coping by partner were associated with both patients' and partners' lower satisfaction with sex life. Subjects generally had high satisfaction levels with the module content (65-85%). Qualitative analysis found five satisfaction themes: managing expectations, couple communication, fostering couple coping and intimacy, increasing knowledge about rehabilitation, and not being alone.
CONCLUSIONS: Online psychosexual support for couples can succeed in impacting knowledge, sexual communication, loss and grief, and negative coping; more engaged couples experience the greatest benefits. Further refinements to the content and format may lead to larger impacts as the intervention is made available to a national audience giving patients and providers an important resource.
